Additionally, the administration of recombinant kallistatin has been shown to significantly reduce inflammatory responses in various animal models of myocardial ischemia, hypertension, or chronic inflammatory diseases [22,24,33,36]. This evidence concerns the gene SERPINA4 and hypertensive disorder.